Accéder au contenu
Merck

[Management of gynecomastia induced by bicalutamide].

Annales d'urologie (2007-03-17)
E Haddad
RÉSUMÉ

Adjuvant bicalutamide monotherapy after radical prostatectomy improves the overall survival in patients with locally advanced prostate cancer. The main adverse event of the nonsteroidal antiandrogen is the development of gynecomastia against which prophylactic breast irradiation can be administered. Therapeutic local radiotherapy using a very small number of fractions is a well-tolerated management option. Symptom improvement is observed in about half of the patients. Radiotherapy-related adverse effects are often mild (erythema, skin irritation) and transient. Tamoxifen has been also shown to be effective in prevention and treatment of gynecomastia induced by adjuvant therapy by bicalutamide in two-third of patients. Long-term safety of this prophylactic and therapeutic approach needs to be investigated through appropriate trials. Further evaluation of the optimal dose and duration of treatment with tamoxifen in this setting is required.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Bicalutamide (CDX), ≥98% (HPLC), powder
Bicalutamide, European Pharmacopoeia (EP) Reference Standard
Bicalutamide for system suitability, European Pharmacopoeia (EP) Reference Standard